多发性骨髓瘤患者自体造血干细胞移植后生活质量恢复轨迹与症状负担
该研究为BMT CTN 0702随机对照试验的二次分析,纳入758例接受单次自体造血干细胞移植的多发性骨髓瘤患者,分析移植后4年内FACT-BMT评分及17项症状负担。结果显示FACT-BMT评分在移植后1年内改善并随后保持稳定,1年时38%患者报告低症状负担,基线低症状负担、年龄较大和在职状态与1年低症状负担相关。
要点
- 自体造血干细胞移植后1年内FACT-BMT评分改善并保持稳定至4年。
- 1年时38%患者报告低症状负担,4年时为32%。
- 基线低症状负担、年龄较大和在职状态与1年低症状负担相关。
核心结论
- 多发性骨髓瘤患者在接受自体造血干细胞移植并实现疾病控制后,FACT-BMT及其子量表评分在移植后1年内恢复至人群常模水平,但许多患者在1年及以后仍报告部分症状为中重度。
研究设计与样本
- BMT CTN 0702随机对照试验的二次分析,比较单次自体造血干细胞移植后三种治疗干预的结局,共纳入758例患者。
- 分析移植后4年内FACT-BMT评分,并通过17项个体症状的应答评估症状负担,症状评分0-2分为无/轻度,3或4分为中度/重度。
- 1年时无中度/重度症状评分的患者被认为低症状负担;入组时平均年龄55.5岁,17%为非裔美国人,中位随访6年(范围0.4-8.5年)。
主要发现
- FACT-BMT评分在入组至1年间改善,此后保持稳定。
- 低症状负担患者比例在基线为27%,1年为38%,移植后4年为32%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early autologous hematopoietic cell transplantation (AHCT) with post-transplant maintenance therapy is standard of care in multiple myeloma (MM). While short-term quality of life (QOL) deterioration after AHCT is known, the long-term trajectories and symptom burden after transplantation are largely unknown. Toward this goal, a secondary analysis of QOL data of the BMT CTN 0702, a randomized controlled trial comparing outcomes of three treatment interventions after a single AHCT (N = 758), was conducted. FACT-BMT scores up to 4 years post-AHCT were analyzed. Symptom burden was studied using responses to 17 individual symptoms dichotomized as 'none/mild' for scores 0-2 and 'moderate/severe' for scores of 3 or 4. Patients with no moderate/severe symptom ratings were considered to have low symptom burden at 1-year. Mean age at enrollment was 55.5 years with 17% African Americans. Median follow-up was 6 years (range, 0.4-8.5 years). FACT-BMT scores improved between enrollment and 1-year and remained stable thereafter. Low symptom burden was reported by 27% of patients at baseline, 38% at 1-year, and 32% at 4 years post-AHCT. Predictors of low symptom burden at 1-year included low symptom burden at baseline: OR 2.7 (1.8-4.1), p < 0.0001; older age: OR 2.1 (1.3-3.2), p = 0.0007; and was related to being employed: OR 2.1 (1.4-3.2), p = 0.0004). We conclude that MM survivors who achieve disease control after AHCT have excellent recovery of FACT-BMT and subscale scores to population norms by 1-year post-transplant, though many patients continue to report moderate to severe severity in some symptoms at 1-year and beyond.
引用
- D'Souza A, Brazauskas R, Stadtmauer EA, et al. Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. Am J Hematol. 2022. PMID: 35567778. doi:10.1002/ajh.26596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。